Japan Lipid Lowering Drugs Market Insights Forecasts to 2033

• The Japan Lipid Lowering Drugs Market Size was valued at USD 481.5 Million in 2023.
• The Market Size is Growing at a CAGR of 4.75% from 2023 to 2033
• The Japan Lipid Lowering Drugs Market Size is Expected to reach USD 765.5 Million by 2033

The Japan Lipid Lowering Drugs Market Size is anticipated to Exceed USD 765.5 Million by 2033, Growing at a CAGR of 4.75% from 2023 to 2033. The increasing incidence of cardiovascular diseases, Growing prevalence of obesity & lifestyle-related diseases, as well as government initiatives and healthcare policies are driving the Growth of the lipid lowering drugs Market in the Japan.     

Market Overview

Lipid-lowering drugs referred to as antihyperlipidemic agents, are pharmaceuticals used for lowering the lipid and lipoproteins in the blood. As per the Vital Statistic Report, heart disease are second most common cause of mortality with more than 310,000 deaths annually. The increasing prevalence of cardiac diseases in the country surges the demand for lipid-lowering drugs as high lipid levels in the blood are significantly responsible for causing cardiovascular diseases. Hyperlipidemia is the most common lipid disorder which can lead to heart attack or stroke if untreated. There are several cholesterol-lowering drugs are approved for treating cholesterol disorders. Statins effectively lower the LDL-C level in the blood by as much as 60%. There is an advancement in lipid-lowering drugs including PCSK9 inhibitors which is a new class of drugs belonging to the lipid-lowering drug category. The growing R&D activities for the innovation and development of lipid lowering drugs are contributing to market growth.

Report Coverage

This research report categorizes the market for the Japan lipid lowering drugs market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Japan lipid lowering drugs market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Japan lipid lowering drugs market.

Driving Factors

Cardiovascular diseases have a significant impact on life expectancy, healthy life expectancy, and medical costs in Japan. Further, the crude mortality rate of heart disease in Japan has been increasing year by year with the aging population. Further, obesity may lead to unhealthy cholesterol levels contributing to dyslipidemia. Other lifestyle-related diseases including diabetes, hypertension, heart diseases, cerebrovascular diseases, cancer, etc. are likely to increase the risk of high cholesterol level in the body. These factors are significantly driving the market for lipid lowering drugs. The approach led by government organizations to spreading awareness about cardiovascular diseases and their preventive measures is promoting the market. For instance, the prevention of cerebrovascular and cardiovascular disease, as well as proper knowledge about these conditions, are being promoted by the Japanese National Plan. The presence of several healthcare policies in Japan are also responsible for driving the market. 

Restraining Factors

Patient adherence and compliance issues associated with lipid-lowering therapies owing to the complexity of medication schedules, side effects, and lack of awareness about the therapy are challenging the Japan lipid lowering drugs market.

Market Segmentation

The Japan Lipid Lowering Drugs Market share is classified into drug, indication, and distribution channel.

• The statins & combination segment dominated the market with the largest market share in 2023.

The Japan lipid lowering drugs market is segmented by drug into statins & combination, PCSK9 inhibitors, bile acid sequestrants, fibrates, cholesterol absorption inhibitors, and others. Among these, the statins & combination segment dominated the market with the largest market share in 2023. Statins are the anti-hyperlipidemic drugs that mediate the lowering of cholesterol and triglyceride levels by inhibiting cholesterol biosynthesis in the body. Statin combination therapy helps to reduce the risk of cardiovascular events. For instance, combination therapy of statin with non-statin drug ezetimibe reduces the risk of heart attack and stroke.

• The hypercholesterolemia segment accounted for the largest market share in 2023.

The Japan lipid lowering drugs market is segmented by indication into hypercholesterolemia, coronary artery disease, and high triglycerides. Among these, the hypercholesterolemia segment accounted for the largest market share in 2023. Hypercholesterolemia is characterized by high levels of cholesterol in the blood which is responsible for increased chances of heart disorders. Hypercholesterolemia can be genetic called familial hypercholesterolemia (FH) is features a high level of LDL-C (low-density cholesterol level). Acute coronary syndrome (ACS) is frequently the initial clinical sign of FH due to underdiagnosis. The proportion of FH patients who were hospitalized due to ACS was 7.2%. This surges the market demand for lipid lowering drugs. 

• The retail pharmacies segment dominated the Japan lipid lowering drugs market during the forecast period.       

Based on the distribution channel, the Japan lipid lowering drugs market is divided into retail pharmacies, hospital pharmacies, and online pharmacies. Among these, the retail pharmacies segment dominated the Japan lipid lowering drugs market during the forecast period. Retail pharmacies allow face-to-face interaction with pharmacists for personalized consultations. Consumer preference for retail pharmacies owing to better assistance and advice from educated individuals and ease of accessibility are driving the market in the retail pharmacies segment.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Japan lipid lowering drugs market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Novartis Pharma K.K.
• Sun Pharma Japan Limited
• Otsuka Pharmaceutical Co., Ltd.
• Taisho Pharmaceutical Co., Ltd.
• Senju Pharmaceutical Co., Ltd.
• AbbVie GK
• Janssen Pharmaceuticals K.K.
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In January 2024, Ultragenyx obtains marketing authorization for Evkeeza® Intravenous Drip Infusion 345mg for the treatment of patients with homozygous familial hypercholesterolemia (HoFH) in Japan.

Market Segment

This study forecasts revenue at Japan, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the Japan Lipid Lowering Drugs Market based on the below-mentioned segments:

Japan Lipid Lowering Drugs Market, By Drug

• Statins & Combination
• PCSK9 Inhibitors
• Bile Acid Sequestrantd
• Fibrates
• Cholesterol Absorption Inhibitors
• Others

Japan Lipid Lowering Drugs Market, By Indication

• Hypercholesterolemia
• Coronary Artery Disease
• High Triglycerides

Japan Lipid Lowering Drugs Market, By Distribution Channel

• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies